Healthcare provider profile · identity verified

Ritesh S Patel, MD

Allopathic & Osteopathic Physicians|Internal Medicine|Clinical Cardiac Electrophysiology · TAMPA, FL · NPI 1063945004

Profile state: payments only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Ritesh S Patel, MD received $9,065.03 in general payments during 2025 across 120 reported records.

Medtronic, Inc. accounted for 43.6% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 26 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$9,065.03

120 reported records · 9 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Medtronic, Inc. Medtronic, Inc.
exact · evidence 2025-07-22
$3,948.7343.6%522025
Abbott Laboratories Unresolved — no canonical attribution shown $1,454.6616.1%202025
Biosense Webster, Inc. Unresolved — no canonical attribution shown $1,169.4712.9%202025
Philips North America LLC Unresolved — no canonical attribution shown $1,138.5612.6%82025
BIOTRONIK INC. Unresolved — no canonical attribution shown $1,136.2112.5%142025
Boston Scientific Corporation Unresolved — no canonical attribution shown $157.741.7%32025
Kestra Medical Technology Services, Inc. Unresolved — no canonical attribution shown $23.500.3%12025
AtriCure, Inc. Unresolved — no canonical attribution shown $22.110.2%12025
AstraZeneca Pharmaceuticals LP Unresolved — no canonical attribution shown $14.050.1%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$4,853.15100
Travel and Lodging$4,005.5419
Education$206.341

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
CARTO 3
Normalized: carto 3
Device Biosense Webster, Inc. $1,169.47 20 2025
Source payment records
AVEIR
Normalized: aveir
Device Abbott Laboratories $835.01 6 2025
Source payment records
EVERA MRI XT DR SURESCAN
Normalized: evera mri xt dr surescan
Device Medtronic, Inc. $829.64 7 2025
Source payment records
MICRA
Normalized: micra
Device Medtronic, Inc. $787.23 12 2025
Source payment records
IGT Devices Undivided
Normalized: igt devices undivided
Device Philips North America LLC $732.09 5 2025
Source payment records
AFFERA MAPPING SYSTEM
Normalized: affera mapping system
Device Medtronic, Inc. $520.63 8 2025
Source payment records
AZURE XT DR MRI SURESCAN
Normalized: azure xt dr mri surescan
Device Medtronic, Inc. $461.85 13 2025
Source payment records
LM Undivided
Normalized: lm undivided
Device Philips North America LLC $406.47 3 2025
Source payment records
ENSITE PRECISION
Normalized: ensite precision
Device Abbott Laboratories $362.08 3 2025
Source payment records
OMNIASECURE MRI SURESCAN
Normalized: omniasecure mri surescan
Device Medtronic, Inc. $321.24 2 2025
Source payment records
COBALT DR MRI SURESCAN
Normalized: cobalt dr mri surescan
Device Medtronic, Inc. $304.02 3 2025
Source payment records
ENSITE
Normalized: ensite
Device Abbott Laboratories $206.34 1 2025
Source payment records
WATCHMAN FLX
Normalized: watchman flx
Device Boston Scientific Corporation $157.74 3 2025
Source payment records
BIOMONITOR
Normalized: biomonitor
Device BIOTRONIK INC. $144.08 1 2025
Source payment records
AMVIA EDGE
Normalized: amvia edge
Device BIOTRONIK INC. $92.37 1 2025
Source payment records
NUVISION ICE CATHETER
Normalized: nuvision ice catheter
Device Biosense Webster, Inc. $70.47 3 2025
Source payment records
AURORA EV-ICD MRI SURESCAN
Normalized: aurora ev icd mri surescan
Device Medtronic, Inc. $60.30 2 2025
Source payment records
JOT DX
Normalized: jot dx
Device Abbott Laboratories $38.85 7 2025
Source payment records
Assure WCD
Normalized: assure wcd
Device Kestra Medical Technology Services, Inc. $23.50 1 2025
Source payment records
OCTARAY MAPPING CATHETER
Normalized: octaray mapping catheter
Device Biosense Webster, Inc. $23.46 2 2025
Source payment records
EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX
Normalized: epi sense guided coagulation system with visitrax
Device AtriCure, Inc. $22.11 1 2025
Source payment records
PULSESELECT
Normalized: pulseselect
Device Medtronic, Inc. $19.48 1 2025
Source payment records
BREZTRI
Normalized: breztri
Drug AstraZeneca Pharmaceuticals LP $14.05 1 2025
Source payment records
ACCENT
Normalized: accent
Device Abbott Laboratories $12.38 3 2025
Source payment records
QDOT MICRO
Normalized: qdot micro
Device Biosense Webster, Inc. $10.00 1 2025
Source payment records
Acticor 7 VR-T DX
Normalized: acticor 7 vr t dx
Device BIOTRONIK INC. $5.75 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $9,065.03 · 120 records Medtronic, Inc. ACCENT, AFFERA MAPPING SYSTEM, AMVIA EDGE, AURORA EV-ICD MRI SURESCAN, AVEIR, AZURE XT DR MRI SURESCAN, Acticor 7 VR-T DX, Assure WCD, BIOMONITOR, BREZTRI, CARTO 3, COBALT DR MRI SURESCAN, ENSITE, ENSITE PRECISION, EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX, EVERA MRI XT DR SURESCAN, IGT Devices Undivided, JOT DX, LM Undivided, MICRA, NUVISION ICE CATHETER, OCTARAY MAPPING CATHETER, OMNIASECURE MRI SURESCAN, PULSESELECT, QDOT MICRO, WATCHMAN FLX
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error